DNA methylation markers and early recurrence in stage I lung cancer - PubMed (original) (raw)
. 2008 Mar 13;358(11):1118-28.
doi: 10.1056/NEJMoa0706550.
Craig M Hooker, Emi Ota-Machida, Yu Han, Mingzhou Guo, Stephen Ames, Sabine Glöckner, Steven Piantadosi, Edward Gabrielson, Genevieve Pridham, Kristen Pelosky, Steven A Belinsky, Stephen C Yang, Stephen B Baylin, James G Herman
Affiliations
- PMID: 18337602
- DOI: 10.1056/NEJMoa0706550
Free article
DNA methylation markers and early recurrence in stage I lung cancer
Malcolm V Brock et al. N Engl J Med. 2008.
Free article
Abstract
Background: Despite optimal and early surgical treatment of non-small-cell lung cancer (NSCLC), many patients die of recurrent NSCLC. We investigated the association between gene methylation and recurrence of the tumor.
Methods: Fifty-one patients with stage I NSCLC who underwent curative resection but who had a recurrence within 40 months after resection (case patients) were matched on the basis of age, NSCLC stage, sex, and date of surgery to 116 patients with stage I NSCLC who underwent curative resection but who did not have a recurrence within 40 months after resection (controls). We investigated whether the methylation of seven genes in tumor and lymph nodes was associated with tumor recurrence.
Results: In a multivariate model, promoter methylation of the cyclin-dependent kinase inhibitor 2A gene p16, the H-cadherin gene CDH13, the Ras association domain family 1 gene RASSF1A, and the adenomatous polyposis coli gene APC in tumors and in histologically tumor-negative lymph nodes was associated with tumor recurrence, independently of NSCLC stage, age, sex, race, smoking history, and histologic characteristics of the tumor. Methylation of the promoter regions of p16 and CDH13 in both tumor and mediastinal lymph nodes was associated with an odds ratio of recurrent cancer of 15.50 in the original cohort and an odds ratio of 25.25 when the original cohort was combined with an independent validation cohort of 20 patients with stage I NSCLC.
Conclusions: Methylation of the promoter region of the four genes in patients with stage I NSCLC treated with curative intent by means of surgery is associated with early recurrence.
Copyright 2008 Massachusetts Medical Society.
Comment in
- DNA methylation in lung cancer.
Toyooka S, Matsuo K, Gazdar AF. Toyooka S, et al. N Engl J Med. 2008 Jun 5;358(23):2513; author reply 2514. doi: 10.1056/NEJMc080835. N Engl J Med. 2008. PMID: 18525051 No abstract available. - DNA methylation in lung cancer.
Park IK. Park IK. N Engl J Med. 2008 Jun 5;358(23):2513; author reply 2514. N Engl J Med. 2008. PMID: 18536092 No abstract available. - DNA methylation in lung cancer.
Riaz N. Riaz N. N Engl J Med. 2008 Jun 5;358(23):2514; author reply 2514. N Engl J Med. 2008. PMID: 18536093 No abstract available. - DNA methylation in lung cancer.
Tezcan H. Tezcan H. N Engl J Med. 2008 Jun 5;358(23):2514; author reply 2514. N Engl J Med. 2008. PMID: 18536094 No abstract available.
Similar articles
- Promoter hypermethylation of RASSF1A and RUNX3 genes as an independent prognostic prediction marker in surgically resected non-small cell lung cancers.
Yanagawa N, Tamura G, Oizumi H, Kanauchi N, Endoh M, Sadahiro M, Motoyama T. Yanagawa N, et al. Lung Cancer. 2007 Oct;58(1):131-8. doi: 10.1016/j.lungcan.2007.05.011. Epub 2007 Jul 2. Lung Cancer. 2007. PMID: 17606310 - Cohypermethylation of p16 and FHIT promoters as a prognostic factor of recurrence in surgically resected stage I non-small cell lung cancer.
Kim JS, Kim JW, Han J, Shim YM, Park J, Kim DH. Kim JS, et al. Cancer Res. 2006 Apr 15;66(8):4049-54. doi: 10.1158/0008-5472.CAN-05-3813. Cancer Res. 2006. PMID: 16618724 - Tumor-specific methylation in bronchial lavage for the early detection of non-small-cell lung cancer.
Kim H, Kwon YM, Kim JS, Lee H, Park JH, Shim YM, Han J, Park J, Kim DH. Kim H, et al. J Clin Oncol. 2004 Jun 15;22(12):2363-70. doi: 10.1200/JCO.2004.10.077. J Clin Oncol. 2004. PMID: 15197197 - Aberrant methylation of H-cadherin (CDH13) promoter is associated with tumor progression in primary nonsmall cell lung carcinoma.
Kim JS, Han J, Shim YM, Park J, Kim DH. Kim JS, et al. Cancer. 2005 Nov 1;104(9):1825-33. doi: 10.1002/cncr.21409. Cancer. 2005. PMID: 16177988 Review. - Prediction of recurrence after complete resection in patients with NSCLC.
Uramoto H, Tanaka F. Uramoto H, et al. Anticancer Res. 2012 Sep;32(9):3953-60. Anticancer Res. 2012. PMID: 22993343 Review.
Cited by
- The Overlooked Cornerstone in Precise Medicine: Personalized Postoperative Surveillance Plan for NSCLC.
Jiang C, Zhang Y, Deng P, Lin H, Fu F, Deng C, Chen H. Jiang C, et al. JTO Clin Res Rep. 2024 Jun 27;5(8):100701. doi: 10.1016/j.jtocrr.2024.100701. eCollection 2024 Aug. JTO Clin Res Rep. 2024. PMID: 39188582 Free PMC article. Review. - Fluorimetric detection of DNA methylation by cerium oxide nanoparticles for early cancer diagnosis.
Adampourezare M, Nikzad B, Amini M, Sheibani N. Adampourezare M, et al. Heliyon. 2024 Mar 23;10(7):e28695. doi: 10.1016/j.heliyon.2024.e28695. eCollection 2024 Apr 15. Heliyon. 2024. PMID: 38586346 Free PMC article. - Blood-based DNA methylation in advanced Nasopharyngeal Carcinoma exhibited distinct CpG methylation signature.
Chatterjee K, Mal S, Ghosh M, Chattopadhyay NR, Roy SD, Chakraborty K, Mukherjee S, Aier M, Choudhuri T. Chatterjee K, et al. Sci Rep. 2023 Dec 12;13(1):22086. doi: 10.1038/s41598-023-45001-w. Sci Rep. 2023. PMID: 38086861 Free PMC article. - Air pollutants in bronchoalveolar lavage fluid and pulmonary tuberculosis: A mediation analysis of gene-specific methylation.
Liu Q, Ji Y, Wang L, Li Z, Tao B, Zhu L, Lu W, Martinez L, Zeng Y, Wang J. Liu Q, et al. iScience. 2023 Nov 3;26(12):108391. doi: 10.1016/j.isci.2023.108391. eCollection 2023 Dec 15. iScience. 2023. PMID: 38047067 Free PMC article. - The transcription activity of OTX2 on p16 expression is significantly blocked by methylation of CpG shore in non-promoter of lung cancer cell lines.
Peng H, Fu W, Chang C, Gao H, He Q, Liu Z, Cui M, Wang H, Yu Y, Wu Y, Zhang X, Jiang S, Xu C, Shen X, Zhang Z, Zhou Y, Li D, Wang Q. Peng H, et al. Transl Cancer Res. 2023 Oct 31;12(10):2582-2595. doi: 10.21037/tcr-23-909. Epub 2023 Oct 20. Transl Cancer Res. 2023. PMID: 37969391 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous